In preclinical studies, IL-12 combined with anti-PD-1 monoclonal antibodies has been shown to eliminate established tumors (172), and for the treatment of breast cancer in an animal model, IL-12-based therapy combined with anti-PD-1 monoclonal antibodies yielded promising results. Here, PDCD1 is linked to breast carcinoma.